NETEC Resource Library

Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

Contenu

Click for External Resource*


Click to read full article*


*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.


Item Type

Publication

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Was this resource helpful?


Titre

Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

Sujet

Description

Nipah virus is an emerging pathogen in the Paramyxoviridae family. Upon transmission of Nipah virus from its natural reservoir, Pteropus spp. fruit bats, to humans, it causes respiratory and neurological disease with a case-fatality rate about 70%.

Date

2019-05-29

Citer ce document

Lo, M. K., F. Feldmann, J. M. Gary, R. Jordan, R. Bannister, J. Cronin, N. R. Patel, J. D. Klena, S. T. Nichol, T. Cihlar, S. R. Zaki, H. Feldmann, C. F. Spiropoulou, and E. de Wit. 2019. "Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge." Sci Transl Med 11 (494). doi: 10.1126/scitranslmed.aau9242.

Résumé

Nipah virus is an emerging pathogen in the Paramyxoviridae family. Upon transmission of Nipah virus from its natural reservoir, Pteropus spp. fruit bats, to humans, it causes respiratory and neurological disease with a case-fatality rate about 70%. Human-to-human transmission has been observed during Nipah virus outbreaks in Bangladesh and India. A therapeutic treatment for Nipah virus disease is urgently needed. Here, we tested the efficacy of remdesivir (GS-5734), a broad-acting antiviral nucleotide prodrug, against Nipah virus Bangladesh genotype in African green monkeys. Animals were inoculated with a lethal dose of Nipah virus, and a once-daily intravenous remdesivir treatment was initiated 24 hours later and continued for 12 days. Mild respiratory signs were observed in two of four treated animals, whereas all control animals developed severe respiratory disease signs. In contrast to control animals, which all succumbed to the infection, all remsdesivir-treated animals survived the lethal challenge, indicating that remdesivir represents a promising antiviral treatment for Nipah virus infection.

Accessibilité

Author Manuscript free online through Pub Med Central

Collection